Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole

被引:44
作者
Pfaller, MA
Diekema, DJ
Boyken, L
Messer, SA
Tendolkar, S
Hollis, RJ
机构
[1] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA
[2] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Med, Iowa City, IA 52242 USA
[3] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA
关键词
D O I
10.1128/JCM.41.5.1875-1880.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The performances of the Etest and the disk diffusion methods for testing of the susceptibilities of 235 Candida glabrata isolates to fluconazole and voriconazole were compared with that of the National Committee for Clinical Laboratory Standards (NCCLS) approved standard broth microdilution (BMD) method. The NCCLS method used RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35degreesC. Etest MICs were determined with RPMI 1640 agar containing 2% glucose (RPG agar) and with Mueller-Hinton agar containing 2% glucose and 0.5 mug of methylene blue per ml (MBE agar) and were read after incubation for 48 h at 35degreesC. Disk diffusion testing was performed with MBE agar, 25-mug fluconazole disks, and 1-mug voriconazole disks and by incubation at 35degreesC for 24 h. Overall agreements between the Etest and the BMD MICs obtained with RPG and MBE agars were 91 and 96%, respectively, for fluconazole and 93 and 95%, respectively, for voriconazole. Categorical agreements between the agar-based methods and BMD were 52.3 to 64.7% with fluconazole and 94.8 to 97.4% with voriconazole. The vast majority of the discrepancies by the disk diffusion and Etest methods with fluconazole,were minor errors. The agar-based methods performed well in identifying isolates with resistance to fluconazole and decreased susceptibility to voriconazole.
引用
收藏
页码:1875 / 1880
页数:6
相关论文
共 18 条
[1]   Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates [J].
Arendrup, M ;
Lundgren, B ;
Jensen, IM ;
Hansen, BS ;
Frimodt-Moller, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (05) :521-526
[2]   Quality control limits for broth microdilution susceptibility tests of ten antifungal agents [J].
Barry, AL ;
Pfaller, MA ;
Brown, SD ;
Espinel-Ingroff, A ;
Ghannoum, MA ;
Knapp, C ;
Rennie, RP ;
Rex, JH ;
Rinaldi, MG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3457-3459
[3]   Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods [J].
Barry, AL ;
Pfaller, MA ;
Rennie, RP ;
Fuchs, PC ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1781-1784
[4]   Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation [J].
Kronvall, G ;
Karlsson, I .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (04) :1422-1428
[5]   A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion [J].
Meis, J ;
Petrou, M ;
Bille, J ;
Ellis, D ;
Gibbs, D .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (04) :215-223
[6]   Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species [J].
Morace, G ;
Amato, G ;
Bistoni, F ;
Fadda, G ;
Marone, P ;
Montagna, MT ;
Oliveri, S ;
Polonelli, L ;
Rigoli, R ;
Mancuso, I ;
La Face, S ;
Masucci, L ;
Romano, L ;
Napoli, C ;
Tatò, D ;
Buscema, MG ;
Belli, CMC ;
Piccirillo, MM ;
Conti, S ;
Covan, S ;
Fanti, F ;
Cavanna, C ;
D'Alò, F ;
Pitzurra, L .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (08) :2953-2958
[7]  
National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L
[8]   Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media [J].
Pfaller, MA ;
Messer, SA ;
Karlsson, Å ;
Bolmström, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (09) :2586-2589
[9]   In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. [J].
Pfaller, MA ;
Messer, SA ;
Hollis, RJ ;
Jones, RN ;
Diekema, DJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1723-1727
[10]   Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media [J].
Pfaller, MA ;
Messer, SA ;
Houston, A ;
Mills, K ;
Bolmstrom, A ;
Jones, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) :3715-3717